Tumors Reactivate Late Endothelial Progenitor Gene Program to Sustain Angiogenesis via ITGAV

The June 2026 Cancer Research study combined single-cell RNA-seq and ATAC-seq from eight solid tumors with time-resolved H3K27ac ChIP-seq and Hi-C from human embryonic stem cell to endothelial differentiation. This identified a shared gene regulatory program between late endothelial progenitors and tumor endothelial cells that anti-VEGF therapies fail to fully suppress. ITGAV emerged as the key upregulated mediator; pharmacologic blockade reduced endothelial migration and tube formation in vitro and decreased vascular density plus tumor growth in colorectal xenografts.

Current VEGF inhibitors achieve only transient responses because tumor endothelial cells retain developmental plasticity. By reactivating an embedded progenitor program instead of inventing new pathways, tumors bypass VEGF-centric control. Ligand-receptor analysis implicated multiple tumor-microenvironment signals that reawaken this state, explaining histologic and molecular heterogeneity observed after prolonged anti-angiogenic exposure.

The work reframes endothelial plasticity as a developmental co-option event rather than purely adaptive mutation-driven resistance. Complementary targeting of the progenitor program alongside VEGF blockade could address the durability gap seen in metastatic colorectal, renal, and lung cancers.

Next steps require validation in genetically engineered mouse models with intact immunity and early-phase safety testing of ITGAV-directed agents in patients progressing on standard anti-angiogenics.